(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-N-methyloctahydro-2H-isoindole-2-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-N-methyloctahydro-2H-isoindole-2-carboxamide
• 英文别名: (3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-N-methyl-1,3,3a,4,5,6,7,7a-octahydroisoindole-2-carboxamide
• 化学式: C₂₆H₂₇F₇N₂O₂
• 分子量: 532.501
• InChiKey: FBMOXTLEBXXOOH-GNVOIQCSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindole 、 异氰酸甲酯 以 二氯甲烷 为溶剂， 反应 2.0h， 以80%的产率得到(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-N-methyloctahydro-2H-isoindole-2-carboxamide
  参考文献：
  名称：

  Hydroisoindoline tachykinin receptor antagonists

  摘要：

  本发明涉及某些羟基异吲哚啉化合物，其作为神经激肽-1（NK-1）受体拮抗剂以及缓激肽和特别是P物质的抑制剂而有用。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病，包括呕吐、尿失禁、抑郁症和焦虑症中的用途。

  公开号：

  US20050165083A1

文献信息

• Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence
  申请人：Gottesdiener Keith M.

  公开号：US20090270406A1

  公开（公告）日：2009-10-29

  This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof. In another aspect, this invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof.

  这项发明涉及用于治疗尿频、尿急和尿失禁的组合物，包括(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺及其药学上可接受的盐。另一方面，这项发明涉及用于尿频、尿急和尿失禁的联合疗法，其中一种活性药物是(R)-N-[4-[2-[[2-羟基-2-(吡啶-3-基)乙基]氨基]乙基]苯基]-4-[4-(4-三氟甲基苯基)噻唑-2-基]苯磺酰胺及其药学上可接受的盐。
• Hydroisoindoline Tachykinin Receptor Antagonists
  申请人：Bunda Jaime Lynn

  公开号：US20080280966A1

  公开（公告）日：2008-11-13

  The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

  本发明涉及某些式I的羟基异吲哚化合物，其可用作神经激肽-1（NK-1）受体拮抗剂，以及缓激肽和特别是物质P的抑制剂。本发明还涉及含有这些化合物作为活性成分的制药配方，以及使用这些化合物及其配方治疗某些疾病，包括恶心、尿失禁、抑郁症和焦虑症。
• Potent, Brain-Penetrant, Hydroisoindoline-Based Human Neurokinin-1 Receptor Antagonists
  作者：Jinlong Jiang、Jaime L. Bunda、Geoge A. Doss、Gary G. Chicchi、Marc M. Kurtz、Kwei-Lan C. Tsao、Xinchun Tong、Song Zheng、Alana Upthagrove、Koppara Samuel、Richard Tschirret-Guth、Sanjeev Kumar、Alan Wheeldon、Emma J. Carlson、Richard Hargreaves、Donald Burns、Terence Hamill、Christine Ryan、Stephen M. Krause、WaiSi Eng、Robert J. DeVita、Sander G. Mills

  DOI：10.1021/jm8016514

  日期：2009.5.14

  3-[(3aR,4R,5S,7aS)-5-(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-2H-isoindol-2-yl]-cyclopent-2-en-1-one (17) is a high affinity, brain-penetrant, hydroisoindoline-based neurokinin-1 (NK(1)) receptor antagonist with a long central duration of action in preclinical species and a minimal drug-drug interaction profile. Positron emission tomography (PET) studies in rhesus showed that this compound provides 90% NK(1) receptor blockade in rhesus brain at a plasma level of 67 nM, which is about 10-fold more potent than aprepitant, an NK(1) antagonist marketed for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV and PONV). The synthesis of this enantiomerically pure compound containing five stereocenters includes a Diels-Alder condensation, one chiral separation of the cyclohexanol intermediate, an ether formation using a trichloroacetimidate intermediate, and bis-alkylation to form the cyclic amine.
• HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1711465B1

  公开（公告）日：2007-12-26
• COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1937264B1

  公开（公告）日：2011-06-08